Drug
Abatacept clinical trials
Also written Orencia, Belatacept, Nulojix and BMS-188667.
- studies test it
- 220
- open now
- 30
- in phase 3
- 47
- first study started
- 1995
Keep track of what changes. Save the Abatacept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
220 studies that test it; most in 2013 (23)
| Year | Studies |
|---|---|
| 1995 | 2 |
| 1997 | 1 |
| 2000 | 2 |
| 2001 | 2 |
| 2002 | 4 |
| 2003 | 3 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 13 |
| 2008 | 14 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 9 |
| 2012 | 7 |
| 2013 | 23 |
| 2014 | 16 |
| 2015 | 12 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 9 |
| 2019 | 14 |
| 2020 | 10 |
| 2021 | 12 |
| 2022 | 9 |
| 2023 | 9 |
| 2024 | 5 |
| 2025 | 6 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 7
- Phase 1
- 47
- Phase 2
- 102
- Phase 3
- 47
- Phase 4
- 36
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 67 · Other 153
Bristol-Myers Squibb (62) · National Institute of Allergy and Infectious Diseases (NIAID) (18) · Emory University (5) · NYU Langone Health (5) · University of California, Los Angeles (5) · Duke University (4) · Massachusetts General Hospital (4) · Columbia University (4)
Often tested with
Tested in the same studies.
Tocilizumab (9) · Sirolimus (7) · Adalimumab (7) · Methotrexate (7) · Certolizumab Pegol (6) · Cyclophosphamide (5) · Etanercept (5) · Tofacitinib (5)
Studies
Open first, then newest update. How each study uses Abatacept is read from its arms, and is right about nine times in ten.
Testing it · 220
- Advancing Transplantation Outcomes in ChildrenRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06055608Written as Belatacept
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBelRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT06918990Written as Belatacept
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingPhase 3Duke UniversityNCT06654882Written as Abatacept
- Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingPhase 1National Cancer Institute (NCI)NCT07388563Written as abatacept
- Partial Stem Cell Transplant for Sickle Cell Disease From Matched DonorsRecruitingPhase 1/2National Heart, Lung, and Blood Institute (NHLBI)NCT07599176Written as Abatacept
- Belatacept in Heart TransplantationRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06478017Written as Belatacept
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsRecruitingPhase 3Bristol-Myers SquibbNCT04877288Written as Belatacept
- Abatacept in Immune Checkpoint Inhibitor MyocarditisRecruitingPhase 3Massachusetts General HospitalNCT05335928Written as Abatacept plus
- Abatacept for the Treatment of Giant Cell ArteritisRecruitingPhase 3University of PennsylvaniaNCT04474847Written as Abatacept
- Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell DiseaseRecruitingPhase 2St. Jude Children's Research HospitalNCT07616154Written as Abatacept
- Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung DiseaseRecruitingPhase 2Children's Hospital Medical Center, CincinnatiNCT04925375Written as Abatacept
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Abatacept
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Abatacept
- Comparison of the Effects of Belatacept and Anticalcineurins on Endothelial Function in Renal Transplant Patients - <BELAFENDO>RecruitingPhase 4University Hospital, RouenNCT06291077Written as Belatacept
- Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)RecruitingPhase 1/2Northwell HealthNCT05289167Written as Abatacept
- Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease ProphylaxisRecruitingPhase 2Boston Children's HospitalNCT04380740Written as Abatacept
- Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell TransplantationRecruitingPhase 1Washington University School of MedicineNCT06008808Written as Abatacept
- Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss TherapyRecruitingPhase 2Linda CendalesNCT02310867Written as Belatacept
- Assessment of Biomarker-Guided CNI Substitution In Kidney TransplantationRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05917522Written as Abatacept
- Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingPhase 2/3Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyNCT07366801Written as Abatacept
See all 220 studies that test Abatacept →
Given in every arm · 9 — Abatacept is usual care beside what is tested
- Tolerance by Engaging Antigen During Cellular HomeostasisCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT03504241Written as belatacept
- A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateActive, not recruitingPhase 3Bristol-Myers SquibbNCT04909801Written as Abatacept
- A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)CompletedPhase 4Astellas Pharma Korea, Inc.NCT03737708Written as abatacept
- Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid ArthritisStatus unknownPhase 3Zhejiang Provincial People's HospitalNCT05451615Written as Abatacept
- Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis PatientsCompletedNot applicableUniversity Hospital, MontpellierNCT02547493Written as Abatacept
- Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)Status unknownPhase 4University of CincinnatiNCT04849533Written as Belatacept
- Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid ArthritisCompletedPhase 4Bristol-Myers SquibbNCT02557100Written as Abatacept
- Phase IIIB Subcutaneous Abatacept Monotherapy StudyCompletedPhase 3Bristol-Myers SquibbNCT00547521Written as abatacept
- Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF TherapyCompletedPhase 3Bristol-Myers SquibbNCT00124982Written as Abatacept
As the comparator · 7 — what is tested is compared with Abatacept
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDsCompletedPhase 3AbbVieNCT03086343Written as Abatacept
- Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory MyopathyCompletedPhase 3Bristol-Myers SquibbNCT02971683Written as Abatacept subcutaneous
- Immune Modulators for Treating COVID-19CompletedPhase 3Daniel BenjaminNCT04593940Written as Abatacept
- TOward the Lowest Effective DOse of Abatacept or TocilizumabCompletedPhase 4Assistance Publique - Hôpitaux de ParisNCT01557374Written as Tocilizumab, Abatacept
- Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy SubjectsCompletedPhase 1Momenta Pharmaceuticals, Inc.NCT02923583Written as US-Sourced Orencia®
- Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)CompletedPhase 3Novartis PharmaceuticalsNCT01350804Written as Abatacept
- Efficacy, Pharmacokinetics, Safety, and Immunogenicity Study of Abatacept Administered Subcutaneously to Treat Rheumatoid Arthritis in Japanese PatientsCompletedPhase 2/3Bristol-Myers SquibbNCT01001832Written as Intravenous (IV) abatacept
Codes
What other systems call Abatacept · ClinicalTrials.gg INT006617
- MeSH (NLM) D000069594AbataceptConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 7D0YB67S97ABATACEPTConfirmed FDA, NLM, Wikidata
- RxNorm 614391Confirmed FDA, Wikidata
- Wikidata Q2697833abataceptConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C28898AbataceptOne source FDA
- DrugBank DB01281One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069594 | Abatacept | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 7D0YB67S97 | ABATACEPT | Confirmed FDA, NLM, Wikidata |
| RxNorm | 614391 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2697833 | abatacept | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C28898 | Abatacept | One source FDA |
| DrugBank | DB01281 | — | One source Wikidata |
Also registered as belatacept (UNII E3B2GI648A · RxNorm 1112973).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.